# NeuroSense Therapeutics (NRSN) Stock Price, News & Catalysts
Canonical URL: https://biopharmsignal.com/company/NRSN
## Company Profile
- Ticker: NRSN
- Exchange: NASDAQ
- Sector: Biopharma
- Location: Israel and listed in the U
## Stock Data
- Close: 0.4016 USD
- Market cap: 28879850.400000002 USD
- Last updated: 2026-09-03
## Business Overview
NeuroSense Therapeutics is a biotechnology company focused on neurodegenerative diseases such as ALS and related conditions. Its story centers on trying to develop therapies for some of the hardest diseases in CNS medicine.
## Why The Stock Is Moving

As of Sep 3, 2026, NRSN closed down 2.24% at $0.4016. No new same-company headline was identified in the current news window.

## Geographic Base

NeuroSense is headquartered in Israel and listed in the U.S. market. It sits in neuroscience biotechnology.

## Business Model

The company depends on clinical proof, translational confidence, and capital efficiency while advancing a narrow neurologic pipeline. Investors usually watch early data and strategic developments.

## Landscape Position

NeuroSense occupies a high-catalyst neurodegeneration niche within biotech. The stock is highly dependent on whether its programs can show meaningful neurologic benefit.

## Future Catalysts

- NeuroSense’s catalysts are primeC and its neurodegeneration programs, plus any update that shows the platform can still keep moving. The company still needs human proof.

## Recent News
- 2026-08-31 12:45 EST — [NeuroSense Unveils Accelerated, Capital-Efficient Strategy to Advance PrimeC Toward Potential Approval in ALS](https://biopharmsignal.com/news/NRSN/neurosense-unveils-accelerated-capital-efficient-strategy-to-advance-primec-towa-dc6ea446) — Source: NeuroSense Therapeutics
- 2026-08-13 13:30 EST — [NeuroSense Issues CEO Letter to Shareholders](https://biopharmsignal.com/news/NRSN/neurosense-issues-ceo-letter-to-shareholders-6fc88fab) — Source: NeuroSense Therapeutics
- 2026-08-06 15:29 EST — [NeuroSense Completes PrimeC Pre-NDS Process and Advances Toward December 2026 Filing with Health Canada](https://biopharmsignal.com/news/NRSN/neurosense-completes-primec-pre-nds-process-and-advances-toward-december-2026-fi-0cca2aac) — Source: NeuroSense Therapeutics
- 2026-07-22 12:30 EST — [NeuroSense Advances PrimeC Toward New Drug Submission to Health Canada for ALS](https://biopharmsignal.com/news/NRSN/neurosense-advances-primec-toward-new-drug-submission-to-health-canada-for-als-721c198c) — Source: NeuroSense Therapeutics
- 2026-07-06 12:45 EST — [NeuroSense to Participate in Roth-Hosted KOL Webinar on the Future of ALS Treatment: "A Quest to Outrun ALS"](https://biopharmsignal.com/news/NRSN/neurosense-to-participate-in-roth-hosted-kol-webinar-on-the-future-of-als-treatm-467c5922) — Source: NeuroSense Therapeutics